Parliament clears reform bill replacing jail terms for procedural lapses with graded monetary penalties across key health laws
The company has highlighted setbacks in Phase II studies while outlining fresh regulatory and late-stage development plans for Fibromun and Nidlegy
The company said the increase—up to 20%—takes effect immediately, or as current contracts allow
Industry, policymakers focus on AI-led regulatory harmonisation, FTAs, MSME support and market expansion as exports touch $28.29 billion till February FY26
The SirPAD trial marks a significant milestone in vascular intervention, positioning MagicTouch PTA as a promising future alternative for PAD treatment
Key FDA decisions and pivotal late-stage obesity and breast cancer data could reshape competitive positioning
Its a major breakthrough for women’s ovarian cancer care in Europe
The trial, dubbed MALBEC, marks the first in a broader late-phase development push for MK-8748, with a second NVAMD study expected to begin later this year
The study targets patients with refractory, unresectable microsatellite-stable (MSS)/mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC)
The agreement will combine Biocytogen’s cutting-edge fully human antibody discovery platform with Sihuan Pharmaceutical’s extensive drug development
Subscribe To Our Newsletter & Stay Updated
